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Abstract
Purpose: To investigate the use of extra-orally applied near infra-red (NIR)
phototherapy for the reduction of oral pain secondary to chemo-and
radiation-therapy induced mucositis in adult and pediatric hematopoietic stem
cell transplant (HSCT) patients.
Methods: 80 HSCT were divided into regular (R) and low (L) risk groups,
then to experimental (E) and placebo (P) groups, resulting in 4 groups (ER,
EL, PR, PL). Experimental subjects received (670 (+/- 10) nm galliumaluminum-arsinide light emitting diode (LED) device for 80 sec at an
~50mW/cm2 energy density and power exposure of 4J/cm2. Placebo patients
received the same procedures, but with a placebo phototherapy (identical
device but < 5mW/cm2 energy density). Patients received their respective
light therapy once per day starting on the day of the HSCT (Day 0) and
continued through Day +14. Blinded evaluators examined the patients 3
times per week and scored their oral tissues and patient-reported pain
assessments at each evaluation utilizing the WHO, NCI-CTCAE, and OMAS
scales.
Results: Analysis of the mean scores at each observation demonstrate that
the extra-oral application of phototherapy resulted in a significant reduction in
patient-reported pain between the ER and PR patients (P<0.05) at Day +14
when graded via the WHO criteria. The ER and EL patients were improved in
almost all other categories and assessment scales, but the differences were
not statistically significant.
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Conclusion: Phototherapy demonstrated a significant reduction in patientreported pain as measured by the WHO criteria in this patient population.
Improvement trends were noted in most other assessment measurements.
Keywords: Mucositis, low level laser therapy, photobiomodulation, light
therapy, pain control

Introduction
Hematopoietic stem cell transplant (HSCT) therapy has
progressed tremendously since the first transplant was attempted in
1939. [1] HSCT has become a standard of care for many diseases, and
in some cases, the first choice therapy rather than being a treatment
of last resort. [2] Complications suffered by these patients have been
minimized by advances in infection control and pain management.
However, mucositis throughout the gastrointestinal tract continues to
be an extremely difficult complication to manage. [3] Infections in
ulcerated tissues are life threatening and require aggressive antibiotic
therapy. Severe mucositis compromises the patient’s ability to take
oral medications by mouth, causes significant pain, and interferes with
speech. [4] This can have enormous consequences in very young
children, who sometimes experience developmental regression and
long-standing feeding problems following HSCT. Due to inability to
obtain appropriate nutrition by mouth, parenteral feeding may be
required but cannot fully replace the nutritional value of a healthy oral
diet. Furthermore, it may contribute to liver dysfunction, increasing
morbidity and ultimately the overall success of therapy. [5] Currently,
Kepivance (Palifermin, KGF Amgen Inc.) has been approved by the
FDA for prevention of mucositis in a subpopulation of HSCT patients.
Effective treatment or preventive regimen of oral mucositis (OM)
would be a great advancement in HSCT. Severe OM can lead to
reduction in the dosage and/or schedule of chemotherapy, which can
ultimately reduce the efficacy of treatment. Many potential therapies
have been proposed including granulocyte-macrophage colony
stimulating factor (GM-CSF) [6], epidermal growth factor [7],
keratinocyte growth factor [8], interleukin-11 [9], transforming growth
factor-beta 3 [10], whey growth factor extract-A [11], ice
(cryotherapy) [12], benzydamine [13], and low-power laser light
therapy [14-16]. Whelan et al. demonstrated that near infra-red light
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generated by light emitting diodes (LED’s) at a 670 nm wavelength is
also capable of reducing the severity and duration of OM [17]. While
numerous low-power laser treatment reports indicate that patients
tolerated the intra-oral application of the light therapy, this method of
delivery requires adequate cooperation on the patient’s part, which can
be difficult to achieve in children. An effective extra-oral approach to
this therapy may potentially allow the therapy to be delivered with
minimal discomfort and improved patient cooperation.
The specific aim of this study was to demonstrate the
effectiveness of extra-orally applied near-infra-red light (670nm)
generated by light emitting diodes at reducing the severity of OM pain
in adult and pediatric patients undergoing myoablative therapy prior to
HSCT rescue. It is difficult to predict the development and severity of
oral OM in an individual patient, therefore, the patients in this study
will be dichotomized into regular or low risk groups depending on their
HSCT preparation. All patients undergoing myeloablative therapy are
at risk of developing OM, but there are populations of patients that are
statistically more likely to develop significant lesions. Allogeneic stem
cell transplant (SCT) patients have a higher risk of OM than autologous
SCT patients (18), combined chemoradiation regimens result in higher
OM rates than chemotherapy alone (19), and multiple drug
chemotherapy regimens produce more OM than single drug regimens.
(20)

Methods and Materials
This was a randomized, double-blind, placebo-controlled study
involving consecutively recruited patients who were undergoing
myeloablative therapy followed by autologous, matched related, or
matched, unrelated donor HSCT rescue. The patients were randomized
to either the control group (sham light treatment) or the experimental
group (near-infrared LED light treatment).

Recruitment and Randomization
Prospective participants at the Children’s Hospital of Wisconsin
(CHW), Milwaukee, Wisconsin, the University of Alabama-Birmingham
(UAB) and The Children’s Hospital of Alabama (TCHA), Birmingham,
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Alabama were identified at each institution through their respective
Oncology services. Inclusion criteria included a minimum age of 3
years and sufficient cooperation to accept the treatment and
evaluation periods. Prospective patients were excluded from the study
if they were not expected to be able or willing to cooperate with the
treatment and evaluation periods. Appropriate consent/assent/parental
permission was obtained from all patients as approved by the
Institutional Review Boards of CHW, UAB, and TCHA. All personnel
involved with the delivery of the treatment and assessments were
trained in the methodology and reporting standards.
After consent was obtained, the disease diagnosis and
therapeutic regimen determined whether the patient was deemed a
regular OM risk group patient or a low OM risk group patient. Patients
deemed at regular risk included patients receiving total body
irradiation and an autologous or matched related donor (MRD), a
matched unrelated donor (MUD), or cord blood transplants; patients
receiving high dose chemotherapy and autologous stem cell rescue for
high risk neuroblastoma (carboplatin, etoposide, and
cyclophosphamide or thiotepa based protocols); patients receiving
busulfan/cyclophosphamide or busulfan/ cyclophosphamide/etoposide
and a MRD, MUD, or cord blood transplant for both malignant disease
and/or non-malignant blood or immune disorder. Patients deemed low
risk included patients undergoing transplantation for multiple myeloma
treated with melphalan. Although melphalan is associated with OM,
this single drug regimen warranted the determination of low OM risk.
Patients considered high risk mucositis were excluded from enrollment
and treated with Kepivance.
Consecutive patients were entered into a pre-developed block
randomization schedule. (Figure 1) Four separate groups were
evaluated; an experimental/regular risk group (ER), a placebo/regular
risk group (PR), an experimental/low risk group (EL) and a
placebo/low risk group (PL). If any patient was dropped from the
study, the next patient enrolled was substituted. Only persons
responsible for registering consented patients at participating sites had
access to this randomization schedule via a secure website and
updated it accordingly. Investigators were kept blinded.
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Fig. 1 Flowchart demonstrating recruitment and randomization of
patients
Daily, experimental subjects were exposed to light emitted from
an LED device (Warp 75, Quantum Devices, Barneveld, WI) at a
wavelength of 670 (+/- 10) nm with a power density of ~50 mW/cm2
for eighty (80) seconds, resulting in an energy delivery of 4 J/cm2 to
the extra-oral bilateral cheeks and anterior throat tissues; total patient
dose was 12 J/cm2 /treatment. The light was held in contact or within
2cm of the extra-oral epithelium of the cheeks and throat. For
infection control purposes, a clear plastic film (Allrap, Pinnacle/Dental
Disposables International/TotalCare, Marlboro, MA) covered the device
and it was cleaned with a hospital-approved disinfectant between
patients. Control subjects received a sham treatment with the device,
with the power reduced to 5 mW/cm2. This light intensity
demonstrated no measurable cellular effects in tissue culture studies.
[21] All subjects received individual cloth eye masks to maintain
blinding and to minimize any theoretical risk of eye injury.
Subjects received daily treatment from Day 0 (day of the
transplant) through Day +14. This endpoint was selected to reduce the
potential influence of graft-versus-host mucosal changes. Patients
were assessed at baseline and then thrice weekly (Mon, Wed, Fri).
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These examinations were performed by trained evaluators. Data on
pain and oral examinations were recorded according to World Health
Organization (WHO) cancer therapy standards [22] and the National
Cancer Institute Common Terminology GI Criteria for Adverse Events
(NCI). [23] The Oral Mucositis Assessment scale (OMAS) described by
Sonis [24] was utilized for descriptive purposes. The post-transplant
day on which each evaluation was completed depended on the day of
the week the transplant was provided. All patients received the
baseline evaluation (Evaluation 1) on Day 0. Subsequent evaluations
were provided on Days +1- +3 (Evaluation 2), Day +3-+5 (Evaluation
3), Day +5- +7 (Evaluation 4), Day +8- +10 (Evaluation 5), Day +10+12 (Evaluation 6) and Day +12- +14 (Evaluation 7).
Subjective information was received from a patient-completed
diary form. This form included questions concerning mouth pain and
was accompanied with a visual analog scale (VAS), with anchors of “no
pain” and “most severe pain possible”. For pediatric patients, a WongBaker FACES (FACES) pain scale [25] was included for their reporting
of pain. These two scales were also used by the patient to report the
impact on swallowing, with the anchors “no trouble” and “unable to
swallow anything (including saliva)”. The patients also reported
whether they could eat normally; eat only soft, solid foods; consume
only liquids; or could not tolerate any food or liquids.

Outcome Measures
The primary outcome measure for analysis was the change in
scores from baseline on the WHO Pain Assessment scale for OM,
documented at each evaluation. Secondary outcome measures also
analyzed were incidence of erythema and ulceration of oral tissues,
and the duration of erythema and ulcerated tissues. All evaluators
received training on the appearance of OM lesions and calibration on
scoring the lesions in the OMAS scale.

Sample size and statistics
The study was powered for the primary comparisons between
the experimental and control groups based on 5% alpha and 80%
power. Based on a two-group independent design, the sample size was
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based on detecting a 25% decrease in the mean pain score between
the two groups. Due to the large variation in pain perception between
individuals, the standard deviation is assumed to be no larger than
39%. With the above mentioned alpha and power, the sample size is
estimated to be approximately 40 patients per group, for a total of 80
patients. Chi-square tests were utilized to statistically compare the
outcomes between the two groups. P values less than 0.05 were
considered significant.

Blinding
All personnel directly involved with the delivery the
phototherapy and evaluation of the patients were blinded as to the
treatment arm. The devices constructed to deliver the light included a
switch that allowed the device to deliver both the sham and
experimental treatments. The personnel (trained nurses) delivering
the phototherapy did not know which switch position was the
experimental or placebo power density. The patients did not know to
which treatment arm they were allocated and wore black cloth eye
shields which prevented them from seeing the switch position on the
light. Finally, the evaluators did not know to which treatment arm the
patients had been allocated.

Results
Between March 2007 and April 2009, 85 patients meeting the
inclusion criteria were consecutively recruited and evaluated from the
Oncology services of CHW (22 patients), UAB (54 patients), and TCHA
(11 patients). Five patients were withdrawn; 4 for admittance into an
intensive care unit due to medical complications not associated with
the light therapy and 1 voluntarily withdrew because of lack of
perceived benefit.
Of the final 80 patients, there were 44 males (55%) and 36
females (45%). The mean age of the patients was 37 years, with a
range from 3 to 74. The sex and age distribution of the patients in
each grouping are summarized in Table 1 and the medical diagnosis
and treatment regimen are listed in Table 2. There was a statistically
significant difference in the ages only between the regular risk and low
Supportive Care in Cancer, Vol. 20, No. 7 (July 2012): pg. 1405-1415. DOI. This article is © Springer and permission has
been granted for this version to appear in e-Publications@Marquette. Springer does not grant permission for this article
to be further copied/distributed or hosted elsewhere without the express permission from Springer.

8

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

risk groups (p<0.0001), but no difference in sex or within the
experimental or placebo groups. Note that the age difference in the
low risk group was expected as the low risk group was confined to
patients receiving single agent melphalan for the treatment of
myeloma, a disease seen almost exclusively in adults.

Table 1 Patient age and sex distribution among treatment groups

Table 2 Patient diagnosis and treatment regimen by group assignment

WHO Scales
An exact Mantel-Haenszel Chi-square test was used to compare
ordered assessment scale differences. There was a significant overall
difference (Mantel-Haenszel trend test) in the WHO pain assessment
scale (p=0.0280). Among all patients, there was a significant
difference between Regular/Low risk groups. (p=0.0226), with the low
risk groups exhibiting less pain. Within the low risk patients (EL vs PL),
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there was no significant treatment difference (p=1.0). Within the
regular risk patients (ER vs PR), there was a significant treatment
difference (p=0.0422) with the experimental phototherapy group
exhibiting less pain (44% reduction in mean scores) at the end of the
study period. (Figure 2) There were no significant differences in the
WHO clinical examination scale between any of the groups.

Fig. 2 Mean differences in WHO pain scores from baseline at each
evaluation period

Other Assessment Scales
There were no significant differences in the NCI scales for
clinical examination or function/symptomatic upper GI scores; the
OMAS erythema or ulceration scale; the VAS or FACES scale; or the
diet scale between any of the groups. (p>0.05). These results are
listed in Table 3. Although not statistically significant, many of the data
suggested a trend for the experimental groups to have general
improvements in all of these scales, but not the placebo groups. (Table
4)
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Discussion
Pain from cancer therapy related OM can be a debilitating side
effect that adversely affects the quality of life of these patients. Pain
can result in a decrease in oral nutritional intake which decreases the
overall health of the patient. Discovering methods to control this side
effect while decreasing the need for analgesics would be a tremendous
advancement in the treatment of cancer patients.
The reduction in pain scores in this study are consistent with
other phototherapy studies specifically reporting on OM pain reduction
[14, 16, 26-31], but differed from Wong et al. who reported no
significant difference in pain scores [32]. The fundamental difference
in this study from the previous published reports involves the
application of the light therapy to the extra-oral tissues rather than an
intra-oral application. This extra oral application with an LED device
with a 75cm2 area allowed for the treatment of a large surface area,
reducing the time to apply the therapy to less than 5 minutes per
patient per treatment. The above cited reference articles reported
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treatment times from as low as 5 minutes [28] to as long as 30
minutes [27] per patient per treatment.
Extra-oral application of light has the potential advantages of
delivery of therapy with less invasiveness, reducing the therapy time
by application of the light over a large surface area at once, and less
manipulation of potentially painful tissue when placing the light probes
intra-orally. Conversely, the disadvantage of extra-orally applied light
therapy involves the diminution of the dose applied to deeper target
tissues due to absorption, reflection, and refraction of the light by the
surface tissues. A study by Stolik et al. measured the optical
penetration depths of different wavelengths through different tissues
and found that longer wavelengths penetrated deeper into various
tissues and that the penetration depths varies between 0.2 - 4.01 mm
for 632.8 nm (HeNe laser) to 0.51 – 4.23 mm for 835 nm light. [33]
Enwemeka demonstrated that light attenuation occurs most rapidly in
muscle tissue and that skin does not significantly affect this
attenuation [34] and that this minimal beam scattering should enable
sub-dermal lesion treatments. Our own preliminary data on light
penetration of the human cheek measured a 85.5% reduction in the
power of our LED light device when measured 2 cm from the light
source (the approximate distance the light was held off the cheek
surface in the protocol) to the interior mucosal surface of the cheek
(21.76 + 2.31 mW/cm2 vs. 3.16 + 0.41 mW/cm2) (unpublished data).
At this power density (3.16 + 0.41 mW/cm2), it is estimated we
delivered 0.56 J/cm2 to the mucosal surface. This fluence is slightly
more than one-half of the fluence reported by Corti et al., which is the
lowest published fluence to demonstrate a positive effect on OM [35]
and is slightly less than the fluence delivered by Wong et al. who
demonstrated no improvement in OM. [32]
Another difference in our study from others is the use of light
emitting diodes. Only one other study utilized light emitting diodes
[29], whereas all others utilized a laser. Some investigators have
advocated that coherent light such as that found in laser generated
light therapy is more effective than non-coherent light generated by
light emitting diodes [36]. Karu [21] has stated that the coherence of
the light is not a critical determinant in its biologic effect, and
Enwemeka has further concluded that there is no scientific evidence
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that supports the theoretical advantages that coherent light may have
over non-coherent light. [36]
Another important question that remains to be clearly elucidated
is the mechanism of action by which phototherapy can provide pain
relief. Enwemeka et al. reviewed nine pain control studies and
concluded that these studies had an overall positive effect on pain
control with phototherapy [37] and possible mechanisms of action
were identified. A recent review by Bjordal et al. concluded that there
is strong evidence that low level laser therapy (LLLT) modulates the
inflammatory process and relieves acute pain in the short term and
reviewed some of the potential mechanisms of action. [38] These
included neurophysiologic effects, release of endogenous opioids, local
microcirculatory and angiogenic effects, local anti-inflammatory
effects, biochemical marker effects, and cell and soft tissue effects.
They found a number of controlled laboratory trials that documented
reductions in the levels of PGE2, TNF, interleukin 1, COX-2 expression,
and plasminogen activator, as well as cellular and soft tissue studies
documenting reductions in edema formation, hemorrhagic formation,
neutrophil cell influx, cell apoptosis, and improvements in
microcirculation. Cyclooxygenase-2 is one of the enzymes that convert
arachidonic acid into PGE2, and PGE2 does not by itself cause pain, but
results in a hyperalgesia state which does induce increased pain
perception. [39] Sonis et al. demonstrated in a hamster model that
COX-2 expression paralleled mucositis severity and although it was not
a primary cause of radiation injury, it did play an amplifying role.[40]
Stimulation of epithelial cells, fibroblasts and chondrocytes with
interleukin 1 and tumor necrosis factor-α (TNF-α) results in increased
PGE2 production as well.[41] Mizutani et al. demonstrated a reduction
in serum PGE2 levels after phototherapy with an 830 nm GaAlAr laser
at 1 W.[42] Light therapy may cause a number of small reductions in
the amplification phase of these cytokines during the mucositis
process, thereby reducing the hyperalgesia and pain perception.
This study also failed to show any significant decrease in the
other measures of OM utilized, which is contrary to multiple published
reports. [14-17, 26-31, 35, 43, 44] This may be due to the reduction
of effect of the light caused by the absorption of the power by more
superficial non-target tissues resulting in inadequate light dosing of the
target tissues. Given that the estimated fluence delivered to the
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mucosal surface from the extra-orally applied phototherapy was only
0.56 J/cm2, this appears to be a reasonable critique. However, the
review by Bjordal et al. states that light therapy can effectively radiate
tissue that lies within 10-15mm of the source [38], but these studies
were of osteoarthritic and other musculoskeletal pain disorders and not
mucositis.
Another reason for the lack of improvement in OM parameters
may be associated with the timing of the phototherapy. In this study,
the phototherapy was started on Day 0 of the transplant regimen.
Several other OM studies [14-16, 26-29, 32, 43, 44] started the
phototherapy prior to or with the start of the myeloablation regimen,
usually occurring 2-7 days prior to the transplant, whereas others [17,
30] delivered the phototherapy on or after the day of the transplant or
appearance of the OM. If the injury to the mucosa occurs with the
initiation of the myeloablative therapy, and if phototherapy works by
reducing the amplification of the inflammatory process, starting the
phototherapy at the initial administration of the myeloablative therapy
may have resulted in more favorable OM results.
The low risk patients were statistically significantly older than
the regular risk patients, and this group did not have any significant
differences in their incidence of OM or pain reporting. There may be
several explanations for these phenomena. Firstly, by definition, the
degree of mucosal injury from a single drug, melphalan, placed these
patients in this low risk group. [20] The multiple drug interactions in
the regular risk group can cause significantly more tissue damage and
produce greater amounts cytokines. Since the low risk patients most
likely had lower levels of these pro-inflammatory cytokines, the
proposed interruption in cell signal amplification caused by
photobiomodulation would not have as great an effect. Another
potential explanation is the decreased mitochondrial activities and
increased damaged to mitochondrial DNA associated with human aging
may have resulted in less photobiostimulatory effects of the
mitochondria in this older population. [45] Further research is needed
to elucidate the effects of photobiostimulation on an aging population.
The extra-oral application of LED phototherapy in this study was
shown to have a statistically significant reduction in pain as reported
by the WHO Pain Assessment scale for OM, but not for other mucositis
scoring scales such as the NCI and OMAS scales. Much further
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research is needed through controlled trials to establish the
appropriate timing, dose, power, and fluence of the phototherapy to
determine the optimum therapeutic parameters.
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